IP Library Granted Patent US 7,491,534
Granted Patent B2
US 7,491,534 · App. 10/426,595 · Granted Feb 17, 2009

Methods for altering cell fate to generate T-cells specific for an antigen of interest

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,491,534
App. No.
10/426,595
Granted
Feb 17, 2009
Kind
B2
Abstract

The invention provides methods for altering the expression profile of a cell to convert the cell from one cell type to a desired cell type (e.g., T-cells). These reprogrammed cells may be used in a variety of medical applications for treating a mammal in need of a particular cell type.

Claims (9)

1. A method of reprogramming a cell to express a T-cell receptor (TCR) reactive with an antigen of interest, said method comprising the steps of:

(a) incubating a permeabilized fibroblast cell with an interphase activated T-cell extract under conditions that result in TCR expression in said permeabilized fibroblast cell; and

(b) selecting a cell that expresses a TCR reactive with an antigen of interest.

2. The method of claim 1 , wherein said cell, following step (a), is incubated under conditions that allow the membrane of said cell to reseal.

3. The method of claim 1 , wherein said permeabilized fibroblast cell of step (a) is further incubated with RNA or protein for a T-cell receptor reactive with said antigen of interest.

4. The method of claim 1 , wherein said method further comprises, prior to step (a), incubating said permeabilized fibroblast cell with a mitotic cell extract under conditions that allow chromatin condensation and nuclear envelope breakdown in said permeabilized fibroblast cell.

5. The method of claim 1 , wherein said permeabilized fibroblast cell is a permeabilized human fibroblast cell.

6. The method of claim 1 or 5 , wherein said interphase activated T-cell extract is a human interphase activated T-cell extract.

7. The method of claim 1 , wherein said permeabilized fibroblast cell is generated by incubating a fibroblast cell with streptolysin O.

Assignments (4)
CHANGE OF NAME Recorded Jan 12, 2015
From: SANFORD APPLIED BIOSCIENCES, L.L.C.
To: SAB, LLC
Reel/Frame 034751/0027 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2013
From: KYOWA HAKKO KIRIN CO., LTD.
To: SANFORD APPLIED BIOSCIENCES, L.L.C.
Reel/Frame 029951/0691 →
MERGER Recorded Dec 23, 2008
From: KIRIN PHARMA KABUSHIKI KAISHA
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 022021/0606 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2008
From: KIRIN HOLDINGS KABUSHIKI KAISHA
To: KIRIN PHARMA KABUSHIKI KAISHA
Reel/Frame 021508/0274 →